News | November 29, 2022
Fredun Pharmaceuticals signs two large contracts
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
The pharma laboratory is fully equipped with all the machinery needed to support formulation development, resolve technical challenges, and provide customer demonstrations
In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
The company had responded to the agency and carried out the required corrective actions.
The product is expected to be launched by Q4 FY23.
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The company is focussed on increasing the capacity utilizations while controlling costs
Subscribe To Our Newsletter & Stay Updated
